Stable graft function on low-dose steroid monotherapy in spite of donor-specific antibodies in renal transplantation combined with stem cell infusion

Trivedi, Hargovind L.; Vanikar, Aruna V.; Dave, Shruti D.
May 2013
BMJ Case Reports;May2013, p1
Academic Journal
No abstract available.


Related Articles

  • The Effect of Stem Cell Transplantation on Immunosuppression in Living Donor Renal Transplantation: A Clinical Trial. Trivedi, H. L.; Vanikar, A. V.; Kute, V. B.; Patel, H. V.; Gumber, M. R.; Shah, P. R.; Dave, S. D.; Trivedi, V. B. // International Journal of Organ Transplantation Medicine;2013, Vol. 4 Issue 4, p155 

    Background/Objective: We designed a clinical trial on a group of live-donor renal transplantation (LDRT) patients subjected to pre-transplant stem cell transplantation (SCT) to minimize immunosuppression to low-dose steroid monotherapy. Methods: LDRT patients subjected to pretransplant SCT who...

  • Haematopoietic stem cells can induce specific skin graft acceptance across full MHC barriers. de Vries-van der Zwan, A.; van der Poi, M.A.; Besseling, A.C.; de Waal, L.P.; Boog, C.J.P. // Bone Marrow Transplantation;7/1/98, Vol. 22 Issue 1, p91 

    Previously, we and others have demonstrated in several animal models that the establishment of stable haematopoietic chimerism through allogeneic bone marrow transfusion provides an effective means for the development of specific transplantation tolerance. However, a major limitation to the...

  • Vascular endothelium as a target of immune response in renal transplant rejection. Piotti, Giovanni; Palmisano, Alessandra; Maggiore, Umberto; Buzio, Carlo // Frontiers in Immunology;Oct2014, Vol. 5, p1 

    This review of clinical and experimental studies aims at analyzing the interplay between graft endothelium and host immune system in renal transplantation, and how it affects the survival of the graft. Graft endothelium is indeed the first barrier between self and non-self that is encountered by...

  • Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. Hägglund, H; Remberger, M; Ringden, O // Bone Marrow Transplantation;Dec2014, Vol. 49 Issue 12, p1541 

    The article discusses the follow-up of a randomized trial in 1998 which compares intraosseous (i.o.) and i.v. transplantation of allogeneic haematopoietic stem cells. The probability of chronic graft versus host disease (GVHD) was deemed similar to both transplantation. Induction of persistent...

  • Cisplatin.  // Reactions Weekly;Aug2015, Vol. 1566 Issue 1, p65 

    An abstract of the article "Donor-specific anti-HLA antibodies after bone-graft transplantation. Impact on a subsequent renal transplantation: a case report," by G. Mosconi and colleagues is presented.

  • B cells in renal transplantation: pathological aspects and therapeutic interventions. Barnett, Nicholas; Dorling, Anthony; Mamode, Nizam // Nephrology Dialysis Transplantation;Mar2011, Vol. 26 Issue 3, p767 

    B cells are vital in renal transplantation. B2 cells are part of the adaptive immune system. Activated B cells mature into plasma cells or memory B cells: their life spans can be prolonged by niches. B cells have a wide variety of functions: antibody production, antigen presentation, cytokine...

  • Induction treatment by combining immunoglobulin, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft. Hernández, J. M. Rufino; Moya, E. Cabello; González-Posada, J. M.; Marrero, D. Hernández; Tamajón, L. Pérez; Miranda, D. Marrero; Rebollo, S. García; Urcuyo, B. Martín; Hernández, A. Rodríguez; Maside, A. Franco; del Pino, Y. Barrios; Rodríguez, R. Rodríguez; Cruz, B. Maceira; Ramírez, A. Torres; Ruiz, E. Salido // Nefrologia;04/01/2010, Vol. 30 Issue 2, p252 

    In our University Hospital of the Canary Island we iniciated in May 2008 a induction therapy protocol for sensitized patients receiving cadaveric renal graft using intravenous immunoglobulins, plasmapheresis and rituximab plus immunosuppression with prednisone, tacrolimus and mycophenolate...

  • Acute antibody-mediated rejection in paediatric renal transplant recipients. Kranz, Birgitta; Kelsch, Reinhard; Kuwertz-Bröking, Eberhard; Bröcker, Verena; Wolters, Heiner; Konrad, Martin // Pediatric Nephrology;Jul2011, Vol. 26 Issue 7, p1149 

    ute antibody-mediated rejections (aAMR) after renal transplantation are defined by rapidly deteriorating graft function, detection of donor-specific antibodies (DSA) and characteristic histological features. In adults, anti-rejection strategies comprise intravenous immunoglobulin (IVIG), steroid...

  • Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Kirk, Allan D.; Burkly, Linda C.; Batty, D. Scott; Baumgartner, Roxanne E.; Berning, Justin D.; Buchanan, Kelvin; Fechner, John H.; Germond, Rhonda L.; Kampen, Robert L.; Patterson, Noelle B.; Swanson, S. John; Tadaki, Douglas K.; TenHoor, Christopher N.; White, Leonard; Knechtle, Stuart J.; Harlan, David M. // Nature Medicine;Jun99, Vol. 5 Issue 6, p686 

    CD154 is the ligand for the receptor CD40. This ligand-receptor pair mediates endothelial and antigen-presenting cell activation, and facilitates the interaction of these cells with T cells and platelets. We demonstrate here that administration of a CD154-specific monoclonal antibody (hu5C8)...

  • Biologics in the prevention and treatment of graft rejection. Marks, Reinhard; Finke, J�rgen // Springer Seminars in Immunopathology;Jun2006, Vol. 27 Issue 4, p457 

    Biologics are used in solid organ allografting and hematopoietic stem cell transplantation (HSCT) for the induction and maintenance of immunosuppression. In solid organ transplantation, antibodies targeting T cells are part of induction protocols administered for initiation of immunosuppression...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics